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Abstract: The Imaging Probe Development Center (IPDC), part of the NIH Roadmap for Medical Research Initiative 
(http://nihroadmap.nih.gov/) recently became fully operational at its newly refurbished laboratories in Rockville, MD. The 
IPDC (http://nihroadmap.nih.gov/molecularlibraries/ipdc/) is dedicated to the production of known and novel molecular 
imaging probes, with its services currently being used by the NIH intramural community, although in the future it is in-
tended that the extramural community will also benefit from the IPDC’s resources. The Center has been set up with the 
belief that molecular imaging, and the probe chemistry that underpins it, will constitute key technologies going forward. 
As part of the larger molecular libraries and imaging initiative, it is planned that the IPDC will work closely with scien-
tists from the molecular libraries effort. Probes produced at the IPDC include optical, radionuclide and magnetic reso-
nance agents and may encompass any type of contrast agent. As IPDC is a trans-NIH resource it can serve each of the 27 
Institutes and Centers that comprise NIH so its influence can be expected to impact widely different subjects and disease 
conditions spanning biological research. IPDC is expected to play a key part in interdisciplinary collaborative imaging 
projects and to support translational R&D from basic research through clinical development, for all of the imaging mo-
dalities. Examples of probes already prepared or under preparation are outlined to illustrate the breadth of the chemistries 
undertaken together with a reference outline of the diverse biological applications for which the various probes are in-
tended. 
BACKGROUND 
  In late 2004 the US National Institutes of Health 
launched its Roadmap for Medical Research in the 21
st Cen-
tury (http://nihroadmap.nih.gov/). One of three major themes 
was identified as “New Pathways to Discovery” one of 
which, in turn, comprised the Molecular Libraries and   
Imaging Initiative (http://nihroadmap.nih.gov/molecularli-
braries/). The Libraries Roadmap Initiatives have put in 
place personnel and facilities which enable the large-scale 
screening of hundreds of thousands of small molecules as 
molecular probes which can be used to study the full spec-
trum of cellular and biochemical processes [1]. Data ob-
tained from this massive effort is made available to the pub-
lic and to biomedical researchers throughout the world, and 
this unprecedented access to shared information is expected 
to greatly facilitate new drug development efforts, even for 
heretofore overlooked and/or rare diseases [2,3]. This ap-
proach has been enabled by three disparate complimentary 
technologies reaching maturity, namely the elucidation of the 
complete human genome, advanced robotics and informatics, 
and high throughput chemistry and assay development, lead-
ing to the emergence of ‘chemical genomics as a vital new 
field of study’ [4]. 
  Concomitant with, and complementary to, the Libraries 
Initiatives are the Roadmap Molecular Imaging Initiatives 
which include an imaging agent database (MICAD), an ex-
tramural research effort aimed to dramatically increase the 
sensitivity and specificity of molecular imaging agents, and a 
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core chemistry facility to actually synthesize imaging probes 
– the Imaging Probe Development Center (IPDC) (http:// 
nihroadmap.nih.gov/molecularlibraries/ipdc/). The field of 
molecular imaging has also been undergoing profound 
changes in the last few years spurred by advances in detec-
tion capabilities in the major modalities of magnetic reso-
nance imaging, radionuclide imaging using both single pho-
ton and positron emitting nuclides, and most notably, in fluo-
rescence microscopy [5-12]. One aspect crucial to the con-
tinuing development, broader use and applied clinical trans-
lation of these modalities is the availability of molecular 
probes, which often need to be synthesized in a tailored fash-
ion for each particular application. Recognition of the basic 
underlying need for access to applied chemistry for the pro-
duction of diverse imaging probes was acknowledged as a 
significant barrier to progress in molecular imaging in the 
initial Roadmap discussions and led directly to the formation 
of the IPDC. In a ‘needs’ analysis prior to IPDC formation it 
was noted that only a few small to intermediate size compa-
nies (e.g. Invitrogen, Macrocyclics, etc.) provided special-
ized agents for molecular imaging studies and even then spe-
cialized requests such as a one-time synthesis or modest syn-
thetic runs for testing of even known imaging probes were 
very difficult to secure. Although some academic laborato-
ries have capacity to generate probes for their own studies 
they are very limited in any capacity to provide them for 
other laboratories, leading to a bottleneck in the continuation 
of promising studies by other academic researchers. Finally, 
there was no existing NIH program designed to provide a 
wide range of optical, PET, SPECT, or MRI imaging probes 
to academic investigators. 
  The goal of the IPDC, therefore, is to provide a mecha-
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there is no commercial supply, and to generate novel imag-
ing probes, for biomedical research and clinical applications. 
The IPDC is composed of two major elements, (a) receptor 
modeling/biophysical chemistry, and (b) organic synthesis 
and it is intended that IPDC will complement and support the 
screening centers set up under the Libraries initiative since 
molecular imaging can be seen as a logical downstream ap-
plication of the screening centers discovery efforts. We be-
gan operations after moving into a newly refurbished facility 
near the end of 2006, and initially solicited proposals for 
new imaging probe compositions from the NIH intramural 
community. At the same time we recruited a staff of young 
scientists with diverse interests and expertise related to imag-
ing agents and centered on one or more of classical syn-
thetic, polymer, bioconjugate, metal complexation chemis-
tries or radiochemistry. Along with the new staff, multiple 
new pieces of equipment {Flash, HPLC, FPLC, MS – ES,-
CI, -MALDI, NMRs, etc.} were obtained, installed and 
trained on for the simultaneous preparation of any type of 
composition we might be asked to produce in the coming 
years. In addition to the chemistry production, IPDC has 
biological evaluation facilities which will enable it to per-
form preliminary in vitro testing work, for instance, with 
binding of agents to cellular and protein receptors and sub-
strate turnover studies in enzyme activity assays. A range of 
equipment for cell culture, biosafety cabinets and a variety of 
radiographic and fluorescence imagers including confocal 
microscopy support this biological aspect of the IPDC. This 
‘overlap’ with end-user capabilities is often of great practical 
significance as a checking mechanism in inter-disciplinary 
work performed in different remote laboratories, smoothing 
progress by rapidly overcoming disputable inconsistencies in 
data, which may be seen from different laboratories merely 
by their use of different methods and different equipment. 
On the molecular modeling front IPDC scientists have access 
to the Helix, Biowulf and Double Helix super-cluster com-
puters through the NIH Center for Information Technology. 
This enables scientists to study large molecule interactions 
and small molecule-protein docking studies through the 
AutoDock program. In addition molecular and quantum dy-
namics studies can be performed with smaller molecules to 
determine, for instance, how well sub-units of various mole-
cules interact, as these properties are often important in 
overall fluorescent properties such as fluorescent lifetimes 
and fluorescent resonance energy transfer (FRET). It is 
clearly of vital importance that low molecular weight bind-
ing entities identified from screens and optimized for binding 
via analog syntheses are then only modified via chemical 
handles in positions that have minimal adverse effects on 
their target binding capabilities as well as on the detectable 
agent’s properties. 
  Agents used for molecular imaging at this point in time 
can run the full spectrum from low molecular weight drug-
like molecules through natural products, peptides, nucleo-
tides, sugars and their oligo- and combined conjugates, po-
lymeric, proteinaceous and nanoparticle-like moieties, and 
more; all tagged with one or more of MRI, radionuclidic, 
ultrasound or fluorescently detectable labels.  
IPDC OPERATIONS 
  IPDC operates under the direction of a steering commit-
tee with members drawn from chemists and imaging special-
ists representing most of the Institutes with an interest in 
imaging and/or chemistry. The current make up of this 
committee in shown in Table 1, and represents a broad array 
of interests both with regard to human conditions/diseases 
and areas of basic science studies. All proposals are dis-
cussed in detail at monthly steering committee meetings 
prior to any acceptance or commitment on the part of the 
IPDC. Proposals submitted to the IPDC from the intramural 
NIH community must first be approved for submission by 
the Scientific Director of the Institute wherein the submitting 
scientist is located. In addition, IPDC is overseen by the 
Roadmap’s Office and Portfolio Analysis and Strategic 
Planning (OPASI), which oversees the entire Roadmap pro-
gram, and monitors the IPDC through the Molecular Librar-
ies and Imaging Implementation Group (MLIIG). The 
MLIIG, in turn and as the title implies, oversees the molecu-
lar libraries and imaging programs. Under these umbrellas 
IPDC sent out three solicitations for new project proposals 
from the NIH intramural community during its first year or 
so of existence. 
Table  1.  The Members of the IPDC Steering Committee in 
February 2008 
Robert Balaban (NHLBI)  Allen Braun (NIDCD) 
Martin Brechbiel (NCI)  Henry Bryant (CC) 
Peter Choyke (NCI)  Julie Dyall (NIAID) 
Amir Gandjbakhche (NICHD)  Gary Griffiths (NHLBI) 
Daniel Hommer (NIAAA)  Robert Innis (NIMH) 
Jerry Jennings (NIAID)  Yong Sok Lee (CIT) 
Roderic Pettigrew (NIBIB)  Kenner Rice (NIDA) 
James Sellers (NHLBI)  Richard Siegel (NIAMS) 
Afonso Silva (NINDS)  Craig Thomas (NHGRI) 
 
IPDC PROJECTS 
  Very strong interest and a very strong response through-
out our first year led to the adoption of several dozen pro-
jects for the supply of imaging probes to multiple Institutes 
and Centers within NIH [13]. Over thirty of these projects 
are still ongoing at the time of writing and these will give 
rise to well over 70 individualized probe compositions. The 
projects undertaken by IPDC are broken down by requesting 
Institutes or Centers in Fig. (1), with the largest number of 
projects undertaken on behalf of the National Cancer Insti-
tute (NCI). Probe requests have covered the full spectra of 
chemical compositions used for molecular targeting from 
small molecular weight compounds from medicinal and 
natural products chemists through peptides, nucleotides, sug-
ars and their analogs and oligomers, to compositions based 
on proteins, antibodies and their constructs, dendrimers, 
nanoparticles and liposomes. The detectable agent most re-
quested for compositions is based on fluorescence as an im-
aging beacon, although a significant fraction is related to 
metal complexes for MRI studies and radionuclide-based 
agents.  
 Table  2  lists a selection of the probes made or under 
preparation by composition, detectable agent, the major re-
quested indication, and NIH Institute. Known fluorescent The Imaging Probe Development Center  Current Chemical Genomics, 2008, Volume 1    67 
analogs such as biarsenicals used for site-specific tetracyste-
inyl-protein tagging, which are tricky to make even for a 
well-trained chemist, have now been requested by several 
groups so that around half-a- dozen analogs have been pro-
duced. Requested originally for prion protein infection stud-
ies, they clearly can be applied as a research tool for any 
indication using a tetracysteinyl-labeling strategy. Fluores-
cent dyes are generally quite difficult to work with on a 
chemical basis as such preparations are generally more im-
pure than most chemical starting materials, with confounding 
mixtures often involving several similar compounds as well 
as a selection of isomeric variants, none of which is usually 
of importance to a biological stain- or assay-minded biolo-
gist. Many fluorescent dyes are therefore repurified routinely 
prior to attempting further chemical manipulations.  
  Also widely requested are targeting agents using com-
mon dyes such as the Alexa and cyanine series, for instance 
cholesterol-linked dyes for lipid raft studies and GABA ana-
logs for calcium channel neurotransmitters. Others are in-
volved in basic studies designed to improve dye properties 
such as by modifying fluorescent lifetimes. Particularly in-
teresting probes seek to dramatically improve fluorescent 
imaging by applying ‘caged’ agents, that is, agents that are 
non-fluorescent until an appropriate light source renders 
them so. Such agents are designed to make a dramatic leap 
forward in fluorescent imaging technology by increasing 
sensitivity toward tracking single molecules using photoacti-
vation localization microscopy (PALM). PALM may allow 
researchers to break the diffraction barrier limit by selec-
tively activating and detecting one molecule at a time, re-
peating the procedure numerous times, and then reconstruct-















Fig. (1). Distribution of IPDC projects between NIH intramural 
Institutes and Centers in February 2008. NCI shows the largest 
proportion with a total of 11 of the 34 ongoing projects. 
Table 2.  A Selection of the Molecular Imaging Probes Made or Being Made, their Intended Application, and the NIH Institute 
Initializing the Request 
Composition(s)  Refs  Detectable Agent(s)  Indication(s)  NIH Institute 
Biarsenicals  [14]  Fluorescent protein  Prion infection studies  NIAID 
Thyroid hormones  [15]  Radioiodine  Thyroid disorders  NIDCD 
Affibody
® molecules  [16]  Multiple  Cancer  NCI 
Enzyme substrate  [17]  Fluorescent  PI-PLC  NHLBI 
Dendrimer complexes  [18]  Gadolinium  Vascular studies  NCI 
Caged glutamate  [19]  Fluorescent  Receptor activation  NINDS 
Cholesterol derivatives  [20]  Fluorescent  Lipid rafts  NIEHS 
Chelate complexes  [21]  Fluorescent  Lifetime modulation  NICHD 
Receptor binding agents  [22]  MRI  Breast cancer imaging  NCI 
Nucleotide analogs  [23]  Fluorescent  DNA/RNA probes  NCI 
Adenosine analogs  [24]  Radioiodine  Receptor agents  NIDDK 
Nitroxides [25]  MRI  Radiation  damage  NCI 
Caged molecules  [26]  Fluorescent  Intracellular trafficking  NICHD 
Dopamine antagonists  [27]  Radiolabeled  Neurological disorders  NIDA 
Liposomes [28] Multiple  Colon  cancer  CC 
Dendrimer complexes  [29]  MRI  Gliomas  NCI 
Proteins [30]  Radiolabeled  Amyloid  diseases  NIAMS 
Receptor binding agents  [31]  Fluorescent  Calcium channel agents  NIA 
Gold nanoparticles  [32]  X-ray  HIV-1 binding sites  NCI 
Chelate complexes  [33]  Gadolinium  Neural trafficking  NIMH 
Nucleotides [34]  Fluorescent  HIV-1  studies  NCI 
Peptides [35]  Radiolabeled  Receptor  studies  NIMH 
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proach seeks to make a similar leap toward ‘super-
resolution’ by using a stimulated emission depletion-like 
(STED) strategy employing Förster resonance energy trans-
fer (FRET) pairs. The activatable FRET donor-acceptor 
technique is also applied in several other studies, for instance 
to probe HIV-1 infection mechanisms. This may have gen-
eral implications for all diseases involving similar viral rep-
lication pathways where it greatly improves the target-to-
background ratio. A separate and important series of caged 
probes are non-fluorescent caged glutamates which are used 
in receptor activation studies. 
  Intracellular event studies, outside of infection, are also 
well represented among our probe requests with enzyme 
substrates, for example, with a phosphatidylinositol-specific 
phospholipase C (PI-PLC) already being made. These com-
plex and non-fluorescent multi-phosphatidylinositols will 
become fluorescent upon PLC cleavage and will offer a 
unique way to look at this important class of enzymes. Sepa-
rately, we are working on specifically designed species to 
target intracellular compartments such as lysosomes and 
such agents can have an impact on all lysosomal storage dis-
eases. This project was undertaken with the NCGC (the in-
tramural component of the molecular libraries initiative and 
with whom we share our facility), who successfully identi-
fied targeting moieties of interest, and it represents the first 
example of these two new Roadmap initiatives working to-
gether on a common problem along with the requesting Insti-
tute.  
  Some fluorescent molecules may never be more than 
highly specialized research tools due to their being unavail-
able merely by reason of the difficulties involved in their 
syntheses. However, such agents may also offer special in-
sights into basic cellular processes. Such a series of probes is 
illustrated by the pteridine nucleic acid analogs which are 
fluorescent analogs of the guanosine and adenosine nucleo-
sides. Although very difficult to make, with up to 15 or more 
synthetic steps involved, often on highly labile intermedi-
ates, their unique capacity to be incorporated directly into the 
oligonucleotide chains of DNA and RNA could offer unique 
perspectives on basic oligonucleotide studies. They may 
even have future roles to play in studying the ‘small’ and 
‘micro’ RNAs which are of so much current interest. 
  With MRI reagents the IPDC has been asked to prepare 
low and high molecular weight gadolinium complexes, man-
ganese complexes and nitroxide radicals. These are generally 
used for in vivo studies, although some of the fluorescent 
agents mentioned can also be applied to animal imaging. The 
nitroxides are redox sensitive probes and are envisaged as 
agents for detecting the effects of radiation therapy. They are 
being tested in the context of radiotherapy for glioma. This 
agent potentially has broad application in monitoring radia-
tion therapy. The manganese complexes are intended as bone 
imaging agents, as their chelate structures have appended 
phosphate groups, while it is also an interesting challenge 
from a chemist’s point-of-view as to whether a truly stable 
manganese-chelate complex for in vivo use can be obtained. 
The more common gadolinium ion has been attached to se-
ries of dendrimers using stable chelates for several applica-
tions including vascular and lymphatic imaging and as a new 
set of agents which may be able to traverse blood-brain-
tumor barriers. Low molecular weight gadolinium-labeled 
agents are being studied as neural tracers to map connections 
within the brain.  
  Radiolabeled species represent the majority of animal 
and particularly human-use imaging probes. The IPDC is 
working on low molecular weight radiolabeled thyroid hor-
mones for PET imaging of hypothyroid conditions, radiola-
beled adenosine analogs for imaging adenosine receptors, 
radiolabeled dopamine receptor antagonists for dopamine 
receptor imaging, and radiolabeled vasopressin analogs for 
CNS receptor imaging. Proteins are also under study with 
serum amyloid and ‘Frizzled’ proteins being radiolabeled 
while ongoing radiolabeling work continues with antibodies. 
One satisfying aspect of the IPDC’s scope is that imaging 
sciences, more than most, bridges biotechnology and chem-
istry, and even includes nanotechnology as we are now pro-
ducing nanoparticle-derived agents and are likely to do more 
of such work in the future. On a more compositional note we 
have also prepared targeting liposomes for use in studies 
targeting colon cancer. A notable example of our bridging, 
interdisciplinary position is our ongoing work with Affi-
body
® molecules, which are small enough to be chemically 
synthesized on a peptide synthesizer and also large enough 
to be produced from biotechnological cell fermentations. 
These picomolar affinity constructs represent a new platform 
for disease targeting, can be tagged with detectable agents 
from any of the modalities, and are being developed for both 
therapy and imaging uses. 
THE FUTURE 
  Molecular imaging is becoming ever more important in a 
broad range of studies being done from the smallest intracel-
lular level through intact organisms, including humans. In 
addition, molecular imaging is being adopted by drug mak-
ers and biopharmaceutical firms as a useful adjunct to devel-
opment work, diagnoses, therapy decision-making, and dis-
ease monitoring. Indeed, one might contend that many drugs 
of the future will need to use some kind of imaging work to 
justify their application, and as molecular imaging becomes 
ever more exact and sensitive that position can only be rein-
forced. It is intended that the IPDC will have the capacity to 
assist in the drug development process and in the transfer of 
new agents into initial clinical trials. Our capacity to make 
almost any reasonable imaging probe composition should 
make IPDC a useful resource, especially for scientists who 
may have no current chemistry experience or available col-
laborating chemists and may be blocked from carrying out 
what may be otherwise important investigations. But, as has 
also been demonstrated with our initial projects, even me-
dicinal chemists can make use of the IPDC to do jobs that 
may be too difficult in their own laboratory, even if from just 
a regulatory viewpoint, as for instance with radiolabeling. 
The plethora of new agents being described in the literature 
clearly leaves many bioscientists frustrated that studies can-
not be repeated and expanded in new directions often due to 
lack of chemistry resources, and the IPDC will seek to ad-
dress this issue to the best of its abilities.  
  The IPDC looks forward to addressing the needs of the 
broader imaging community. The initial experience bodes 
well for the ability of IPDC to provide unique imaging 
probes that will provide biologic insights into the mecha-
nisms of a broad spectrum of disease. Meanwhile I encour-The Imaging Probe Development Center  Current Chemical Genomics, 2008, Volume 1    69 
age those of you who are interested to feel free to contact me 
if you have questions about the IPDC or its services, or to 
enquire informally about a prospective molecular imaging 
probe that you may be interested in. I can be reached by 
email at: griffithsgl@mail.nih.gov. 
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